Danish biotechnology company MinervaX ApS and Wacker Biotech, a contract development and manufacturing organisation (CDMO) owned by German chemical company Wacker Chemie AG (ETR:WCH), on Tuesday announced a collaboration to manufacture MinervaX's Group B Streptococcus (GBS) vaccine.
GBS is a major cause of life-threatening infections in newborns and can also affect pregnant women and older adults. There is a significant unmet medical need for a vaccine to prevent these infections.
MinervaX's vaccine candidate is a novel protein-based vaccine that has shown promising results in clinical trials. The company is preparing to start Phase III trials.
Wacker Biotech will manufacture the active ingredients of the vaccine and ensure stable commercial supply. This collaboration aims to address the urgent need for a GBS vaccine.
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
IGC Pharma reports new data supporting IGC-AD1 to treat Alzheimer's
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
ValiRx's subsidiary Inaphaea signs agreement with Xenopat for Patient Derived Cells
IVIEW Therapeutics completes patient recruitment for dry eye disease clinical trial
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Xylyx Bio receives SBIR grant from NIDDK
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
Sareum Holdings secures patent allowance for SDC-1801 in China
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients